HK Stock Market Move | FOSUN INTL (00656) closed nearly 5% higher, with several of its subsidiaries posting strong results; Shanghai Fosun Pharmaceutical's non-recurring net profit rose more than 8% in the first three quarters.

FOSUN INTL (00656) closed up nearly 5%. By the close, it rose 4.74% to HK$4.64, with a turnover of HK$30.6682 million. On the news front, several listed companies under FOSUN INTL recently announced their results. Shanghai Fosun Pharmaceutical's revenue for the first three quarters was RMB30.463 billion, up 3.64% year on year; net profit attributable to shareholders was RMB2.667 billion, up 5.71% year on year; non-recurring net profit attributable to shareholders was RMB1.706 billion, up 8.42% year on year. In addition, FOSUN INTL's Shanghai Yuyuan Tourist Mart recorded revenue of RMB22.981 billion and net profit of RMB168 million for the first three quarters; Fosun High Technology's attributable profit for the first three quarters was RMB505 million, turning from loss to profit year on year. China Securities Co.,Ltd. previously issued a research report stating that FOSUN INTL's health segment includes several listed companies such as Shanghai Fosun Pharmaceutical, HENLIUS, and SISRAM MED, which have achieved a tiered pipeline layout with abundant reserves under research; the happiness segment owns multiple high-quality assets and brands such as Yuyuan Mall, Laomiao Gold, Club Med, and Atlantis Sanya, and continues to advance global development; the wealth segment controls Fidelidade, Peak Reinsurance, HAL, BFC, and others, which continue to maintain steady expansion. Under its plan to "focus on the core business and slim down for health," the company will continue to advance the 8424 strategy in 2026.